India: Natco to launch Hepatitis C drug in India soon

Natco Pharma plans to launch the generic version of Sovaldi, the blockbuster drug used to treat chronic Hepatitis C in India soon. Sovaldi is made by U.S. pharma major Gilead Sciences, and Natco recently entered into a non-exclusive licensing agreement with Gilead to make and sell generic versions of Sovaldi in 91 developing countries.

The company, on Monday, launched the generic version of Sovaldi in Nepal under the brand Hepcinat. The product is priced at Rs.19,900 (US $316.68) per bottle of 28 tablets in Nepal, and covers the treatment duration of three months for a patient.

“We will be launching the drug in the next few weeks in India, and are awaiting approval from the Drugs Controller General of India (DCGI),” M. Adinarayana, Vice-President, Legal & Corporate Affairs, Natco Pharma, told this correspondent.

Read more...

Nepal: Natco Pharma up 4%, launches hepatitis C drug in Nepal

Shares of Natco Pharma gained 4.4 percent intraday on Monday on launching the first generic version of sofosbuvir in Nepal.

Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences Inc., under its brand Sovaldi.

Natco priced its generic medicine at an MRP of Rs 19,900 for a bottle of 28 tablets in Nepal. "Natco markets generic sofosbuvir under its brand HEPCINAT. Natco hopes to launch HEPCINAT in India soon, subject to approval from the Drugs Controller General of India (DCGI)," said the company in its filing to the exchange.

Read more at: http://www.moneycontrol.com/news/buzzing-stocks/natco-pharma4-launches-hepatitis-c-drugnepal_1323547.html?utm_source=ref_article